跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XELJANZ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XELJANZ
Authorized
STANDARD
XELJANZ
Pfizer Canada Ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
01c23f3bf72df8f9
Company
Pfizer Canada Ulc
Type
Standard
Approval Details
Approval Id
01c23f3bf72df8f9
Drug Approval Canada Name
XELJANZ
Product Name
XELJANZ
Status
Marketed
Status Date
2019-01-30
Original Market Date
2019-01-30
Din
02480786
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
90:24.12.92
Atc Original
L04AF01 TOFACITINIB
Atc Name
l 04 af 01
Aig Number
0155550003
Company Name
Pfizer Canada Ulc
Company Address
17300 Trans-Canada Highway, Kirkland, Quebec, Canada, H9J 2M5
Company Detail Path
/organization/pfizer-canada-ulc
Company Information
Pharmaceutical Company Name
Pfizer Canada Ulc
Country Name
Canada
Province Name
Quebec
City Name
kirkland,quebec,country_ca
Address
17300 rte Transcanadienne
Active Ingredients
TOFACITINIB (TOFACITINIB CITRATE)
10 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
01c23f3bf72df8f9
Type
Standard
Back to Health Canada Approvals